Literature DB >> 24514874

In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease.

Victor L Villemagne1, Shozo Furumoto, Michelle T Fodero-Tavoletti, Rachel S Mulligan, John Hodges, Ryuichi Harada, Paul Yates, Olivier Piguet, Svetlana Pejoska, Vincent Doré, Kazuhiko Yanai, Colin L Masters, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura.   

Abstract

PURPOSE: Diagnosis of tauopathies such as Alzheimer's disease (AD) still relies on post-mortem examination of the human brain. A non-invasive method of determining brain tau burden in vivo would allow a better understanding of the pathophysiology of tauopathies. The purpose of the study was to evaluate (18)F-THK523 as a potential tau imaging tracer.
METHODS: Ten healthy elderly controls, three semantic dementia (SD) and ten AD patients underwent neuropsychological examination, MRI as well as (18)F-THK523 and (11)C-Pittsburgh compound B (PIB) positron emission tomography (PET) scans. Composite memory and non-memory scores, global and hippocampal brain volume, and partial volume-corrected tissue ratios for (18)F-THK523 and (11)C-PIB were estimated for all participants. Correlational analyses were performed between global and regional (18)F-THK523, (11)C-PIB, cognition and brain volumetrics.
RESULTS: (18)F-THK523 presented with fast reversible kinetics. Significantly higher (18)F-THK523 retention was observed in the temporal, parietal, orbitofrontal and hippocampi of AD patients when compared to healthy controls and SD patients. White matter retention was significantly higher than grey matter retention in all participants. The pattern of cortical (18)F-THK523 retention did not correlate with Aβ distribution as assessed by (11)C-PIB and followed the known distribution of tau in the AD brain, being higher in temporal and parietal areas than in the frontal region. Unlike (11)C-PIB, hippocampal (18)F-THK523 retention was correlated with several cognitive parameters and with hippocampal atrophy.
CONCLUSION: (18)F-THK523 does not bind to Aβ in vivo, while following the known distribution of paired helical filaments (PHF)-tau in the brain. Significantly higher cortical (18)F-THK523 retention in AD patients as well as the association of hippocampal (18)F-THK523 retention with cognitive parameters and hippocampal volume suggests (18)F-THK523 selectively binds to tau in AD patients. Unfortunately, the very high (18)F-THK523 retention in white matter precludes simple visual inspection of the images, preventing its use in research or clinical settings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24514874     DOI: 10.1007/s00259-013-2681-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  42 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Takahiro Suemoto; Shozo Furumoto; Masako Suzuki; Hiroshi Shimadzu; Hiroyasu Akatsu; Takayuki Yamamoto; Hironori Fujiwara; Miyako Nemoto; Masahiro Maruyama; Hiroyuki Arai; Kazuhiko Yanai; Tohru Sawada; Yukitsuka Kudo
Journal:  J Neurosci       Date:  2005-11-23       Impact factor: 6.167

3.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

4.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

Review 5.  Mutations causing neurodegenerative tauopathies.

Authors:  Michel Goedert; Ross Jakes
Journal:  Biochim Biophys Acta       Date:  2005-01-03

6.  Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.

Authors:  Erik D Roberson; Kimberly Scearce-Levie; Jorge J Palop; Fengrong Yan; Irene H Cheng; Tiffany Wu; Hilary Gerstein; Gui-Qiu Yu; Lennart Mucke
Journal:  Science       Date:  2007-05-04       Impact factor: 47.728

7.  Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Authors:  C M Wischik; P C Edwards; R Y Lai; M Roth; C R Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

8.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

Review 9.  Semantic dementia: a unique clinicopathological syndrome.

Authors:  John R Hodges; Karalyn Patterson
Journal:  Lancet Neurol       Date:  2007-11       Impact factor: 44.182

10.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.

Authors:  David T Chien; A Katrin Szardenings; Shadfar Bahri; Joseph C Walsh; Fanrong Mu; Chunfang Xia; William R Shankle; Alan J Lerner; Min-Ying Su; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

View more
  71 in total

1.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

Review 2.  Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Authors:  Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

3.  Understanding biomarkers of neurodegeneration: Novel approaches to detecting tau pathology.

Authors:  Casey N Cook; Melissa E Murray; Leonard Petrucelli
Journal:  Nat Med       Date:  2015-03       Impact factor: 53.440

Review 4.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

5.  PET imaging of garbage protein in Alzheimer's disease: does it require reappraisal of brain PET analysis?

Authors:  Serge Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05       Impact factor: 9.236

Review 6.  Tau PET imaging in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Ryuichi Harada; Shozo Furumoto; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo
Journal:  Curr Neurol Neurosci Rep       Date:  2014-11       Impact factor: 5.081

Review 7.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

8.  In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain.

Authors:  Jorge Sepulcre; Aaron P Schultz; Mert Sabuncu; Teresa Gomez-Isla; Jasmeer Chhatwal; Alex Becker; Reisa Sperling; Keith A Johnson
Journal:  J Neurosci       Date:  2016-07-13       Impact factor: 6.167

9.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Terry M Therneau; Val J Lowe; David S Knopman; Jeffrey L Gunter; Matthew L Senjem; David T Jones; Kejal Kantarci; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; Prashanthi Vemuri; Denise A Reyes; Ronald C Petersen
Journal:  Alzheimers Dement       Date:  2016-09-30       Impact factor: 21.566

Review 10.  Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Authors:  Jennifer N Rauch; Steven H Olson; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.